A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Akeso
R-Pharm
National Cancer Institute (NCI)
Ningbo Medical Center Lihuili Hospital
Ipsen
Seagen Inc.
Pfizer
Eli Lilly and Company
AstraZeneca
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Astellas Pharma Inc
Institut Cancerologie de l'Ouest
M.D. Anderson Cancer Center
AbbVie
National Cancer Institute (NCI)
Canadian Cancer Trials Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AstraZeneca
National Health Research Institutes, Taiwan
National Cancer Center Hospital East
Baylor College of Medicine
Parabilis Medicines, Inc.
Taiho Oncology, Inc.
J-Pharma Co., Ltd.
NRG Oncology
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Seagen Inc.
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Summit Therapeutics
Astellas Pharma Inc
NRG Oncology
Vejle Hospital
Arcus Biosciences, Inc.
Novartis
UNC Lineberger Comprehensive Cancer Center
Arcus Biosciences, Inc.
Merck Sharp & Dohme LLC